> Pipeline Molecules
> MPDL3280A (anti-PDL1)
(an engineered anti-PDL1 antibody)
designed to harness the body's ownimmune system to fight tumor cells.
Binding of PD-L1 to its receptors, PD-1 and B7.1, on the surface of T cells results in deactivation of the T cells.1
MPDL3280A is designed to target PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, and prevent binding to PD-1 and B7.1 on the surface of T cells.2,3
This may enable the activation of T cells as well as recruit other T cells to attack the tumor, thus empowering the body's own immune system to fight multiple types of cancer.3
© 2015 Genentech USA, Inc. All rights reserved.
Use this Related Resources tool to quickly access topics of interest throughout the site that are relevant to a tumor type.